Groundbreaking NIH Grant for Lactiga's Antibody Research
Lactiga US, Inc., a pioneering biotechnology firm, has secured an important award from the National Institutes of Health (NIH) to enhance the development of its first-in-class secretory IgA (sIgA) antibody targeting inflammatory bowel disease (IBD).
Understanding the Power of Breastmilk-Derived Antibodies
This innovative therapy harnesses the unique benefits of secretory IgA extracted from human breastmilk. It aims to address the issues caused by an overactive immune system that can lead to inflammation. The focus is on acting directly at the intestinal mucosa to neutralize harmful antigens, boosting the barrier function of epithelium, and reducing possible adverse effects.
Lactiga's Vision for Chronic Disease Management
Rik Mehta, Co-Founder and CEO of Lactiga, shared insights into the company's mission: "Our objective is to combat chronic diseases through solutions that leverage the natural defenses of our immune system, instead of relying on synthetic or engineered alternatives." This approach signifies a notable shift in treatment strategies, aiming for safer and more effective outcomes.
The Impact and Scope of Inflammatory Bowel Disease
IBD, which includes conditions like Crohn's disease and ulcerative colitis, poses significant challenges for nearly 3 million Americans, imposing billions in costs to the healthcare system. Current treatments, including biologics and immunosuppressants, often present steep financial burdens and unwanted side effects. Moreover, only about half of the patients experience long-term remission.
Advancing Therapies for Immunodeficient Populations
This NIH support signifies a substantial advancement in Lactiga's research initiatives, allowing the establishment of the first polyclonal antibody platform dedicated to mucosal immunity. The company is actively seeking Series A financing to further develop its sIgA assets specifically for immunocompromised populations, pushing them towards clinical stages of development.
Diving Deeper into Mucosal Immunity
Viraj Mane, Co-Founder and Chief Scientific Officer of Lactiga, emphasized the crucial role of breastmilk-derived sIgA in immunity. He stated, "Our findings indicate that sIgA plays a pivotal role in managing host-microbe dynamics effectively. Through our research, we will uncover the mechanisms by which sIgA neutralizes harmful pathogens and stabilizes mucosal barriers, thereby protecting the gut microbiome. This work lays the groundwork for innovative approaches to oral mucosal immunotherapies."
Collaborative Research for Enhanced Outcomes
To further this research, Lactiga is collaborating with Dr. Tor Savidge from Baylor College of Medicine, an esteemed expert in the interactions between the gut microbiome and immune systems.
About Lactiga
As a biotechnology company, Lactiga dedicates itself to developing unique mucosal antibodies sourced from human breastmilk. They aim to combat chronic diseases and immune dysregulation, particularly in vulnerable populations. Specializing in human secretory IgA (sIgA) therapeutics, Lactiga employs proprietary technology to formulate targeted treatments that address inflammatory, infectious, and chronic health conditions.
Frequently Asked Questions
What is Lactiga's recent achievement?
Lactiga received an award from the NIH to advance its breastmilk-derived antibody research for inflammatory bowel disease.
What is the significance of secretory IgA?
Secretory IgA is crucial for gut immunity, helping to neutralize antigens and maintain mucosal health.
How common is inflammatory bowel disease in the U.S.?
IBD affects nearly 3 million Americans and imposes significant health care costs.
What are Lactiga's future plans?
The company is pursuing Series A financing to accelerate clinical development for their antibody therapies.
Who is collaborating with Lactiga on this research?
Dr. Tor Savidge from Baylor College of Medicine is collaborating with Lactiga for their research initiatives.
